Future Paradigm in Medically Ill Thromboprophylaxis: Individualized (Patient-Level) Risk Adapted Approach with clinical decision support/EHR interoperability: SOA Lecture IMETHA, Greece @NATFthrombosis @PERTConsortium @AnticoagForum @thrombosisday @canvector @ThrombosisCan

.@kaj33 is one of many living with #AFib, a common type of irregular heartbeat. He teamed up with BMS & Pfizer to encourage those with symptoms that could indicate AFib or another condition to speak with a healthcare professional. Learn more: https://t.co/GOeD52Ve1I #WTDay23

It’s arrived. #TikTokXmas #DancingDrBob Text XMASTIKTOK to 70085 to donate £5 to CCLG. Texts will cost the donation amount plus one standard network rate message. Alternatively donate at this link https://t.co/r6DHk454sT @KindlyLoudly

OSCAR-US-H2H observational study comparing rivaroxaban to apixaban for the management of cancer-associated-thrombosis showed that both are effective and safe. No statistical difference in any outcomes was observed after 3 or 6 months of follow up. #ASH22

Educational session in selected populations. Good talk on anticoagulation in women #ASH22. DO NOT STOP ORAL CONTRACEPTIVES AT TIME of START ANTICOAGULATION FOR VTE.

@CPSS_LPCs @joemcmanners @LloydsPharmacy @NHSTayside Advanced clinical pharmacist @KMedlinskiene is inspiring other pharmacists to carry out more research and truly involve patients and the public #PJWomen2Watch @HullHospitals @UniofBradford https://t.co/bgL9IIHVQx

Calling my researcher friends and colleagues! A great opportunity has come up at Leeds Teaching Hospitals - An Embedded Researcher Role! Interested? 👀Read on! 👉

DOACs in LV thrombus. @sbw_cardio @DrSamStraw @UoL_LICAMM @LeedsHospitals @cardiorespLTHT

Did you know what warfarin stands for? A little humor (but mostly true!) from @AnticoagPharmD #aha22

Authoritative guidance from the American Heart Association on the diagnosis and management of left ventricular thrombus. Treatment with DOAC is a reasonable option. https://t.co/SvEDAX4nmm #thrombosis #DOAC

Please Share! A new WTD survey for patients with cancer aims to assess patients' knowledge & satisfaction about the information received by healthcare providers on the potential risks of cancer-associated blood clots & use of blood thinners. https://t.co/Fs1nGI0W2n #WTDay22

Do you prescribe hormone therapies and need a quick reference for effectiveness and VTE risk? Save this chart from the new #RPTH review by @Bloodman and @Clotmaster @bsamuelson_md #HemeTwitter https://t.co/LtvK4P03ZI

If you ever request INR or APTT, this is for you. An one page summary of the key points published today by the @CMAJ. Although the authors are Canadian, the points made apply internationally. https://t.co/DhynNQ5r25

INVICTUS RCT in @NEJM: #Rivaroxaban vs #VKAs in rheumatic AF: Riva failed non-inferiority testing and had ⬆️ primary outcome,💀& stroke c/w VKAs. Departure⏲️from “one size fits all” for #DOACs? Mech valves, APS, etc? https://t.co/mp7kRfmo9r, Editorial https://t.co/TrLlQDNM1q

Aspirin vs Enoxaparin and Symptomatic Venous Thromboembolism in Hip or Knee Arthroplasty https://t.co/TMMEsngPD8 via @JAMA_current part of @JAMANetwork Orthopedic docs and AAOS continue to delude themselves of benefits of ASA @NATFthrombosis @AnticoagForum @ThrombosisCan @isth

UK (& elsewhere) shortage of alteplase/tenecteplase for 6-12 months means urokinase will be drug of choice in non- stroke thrombolysis Probs: -no licensed dose for short infusions - ampoules contain small doses, may need 40- 80 amps for massive PE - need pre- prepared syringes

Most PowerPoint presentations suck. But yours doesn't have to be one of them. Here are 10 simple rules to 10x your next presentation:

The 2022 Chest Perioperative Antithrombotic Guidelines are finally out. They will be practice changing https://t.co/3W5YKSE4Qt @NATFthrombosis @AnticoagForum @PERTConsortium @EuropeanTHA @ThrombosisUK @escardio @ThrombosisCan @canvector @IsthPresident @thrombosisday #thrombosis

Finally published our article on bleeding risk with extended anticoagulation for VTE. Several rules work well and our new CHAP Score is easy. Importantly most fatal bleeds occur in those also high risk for a major bleed. https://t.co/CR4o58HVPn

🚨DOACs are the most prescribed💊in cancer-associated thrombosis patients in Korea, but 🩸 🩸was more common with DOACs than parenteral anticoagulants 💉, particularly in gastrointestinal cancers. ➡️Read the last article published by Kim et al. in T&H: https://t.co/CTVXOuOowG